BioSpace News Archive

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved the newest addition to its feline portfolio — NexGard® COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution).

The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bacthera to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.

Insmed Incorporated today announced that it will host an investor and analyst event on Monday, May 8, 2023.

Mercy BioAnalytics, Inc. today announced the appointment of Myla Lai-Goldman, MD, to its Board of Directors.

Quantum-Si Incorporated today announced the appointments of Katherine Atkinson as Senior Vice President of Demand Generation and Corporate Brand, Alex Hutcheson as Senior Vice President of Sales and Service, Christine Nishiyama as Vice President of Supply Chain and Reagent Manufacturing, and John Vieceli, PhD, as Vice President of Algorithms and Data Science.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data on INBRIJA (levodopa inhalation powder) and OFF Periods at the American Academy of Neurology (AAN) Annual Meeting, taking place in Boston from April 22 to April 27, 2023.

Today, the National Comprehensive Cancer Network® (NCCN®) has published a new addition to its library of patient resources, expanding the information available for breast cancer.

AmerisourceBergen, a global healthcare company, today announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44).